Abstract
The best salvage therapy for protease inhibitor (PI)-resistant HIV-infected patients is still controversial. We measured changes in viral load and CD4 T-lymphocyte counts in 40 PI-resistant patients receiving boosted PI-including or PI-sparing antiretroviral therapy. At multivariate analysis, the only independent predictor of CD4 T-lymphocyte changes at week 24 was a boosted PI-including regimen. In PI-resistant HIV-infected patients, a boosted PI regimen preserves CD4 T lymphocytes from depletion in the medium term compared with a PI-sparing regimen.
Original language | English |
---|---|
Pages (from-to) | 821-823 |
Number of pages | 3 |
Journal | AIDS (London, England) |
Volume | 18 |
Issue number | 5 |
DOIs | |
Publication status | Published - Mar 26 2004 |
ASJC Scopus subject areas
- Immunology and Allergy
- Immunology